Stockholders Approve Equity Incentive Plan with Over 10% Potential Dilution

summarizeSummary

PLUS THERAPEUTICS, INC. stockholders approved an amended equity incentive plan, which could lead to over 10% dilution, alongside the re-election of directors and other routine proposals at its Annual Meeting.

check_boxKey Events

• Equity Incentive Plan Approved

  Stockholders approved the Sixth Amendment and Restatement of the 2020 Stock Incentive Plan. This plan, previously proposed in a March 31, 2026 DEF 14A filing, authorizes the issuance of an additional 740,000 shares (post-reverse split) for compensation. If all authorized shares were issued, dilution would be approximately 10.78%.

• Directors Re-elected

  Six directors — Howard Clowes, An van Es-Johansson, M.D., Richard J. Hawkins, Marc H. Hedrick, M.D., Ronald A. Andrews, and Kyle Guse, Esq., MBA, CPA — were re-elected to the Board of Directors for terms expiring in 2027.

• Auditor Ratified

  The appointment of CBIZ CPAs, P.C. as the independent registered public accounting firm for the 2026 fiscal year was ratified by stockholders.

• Executive Compensation Approved

  Stockholders approved, on an advisory basis, the compensation of the company's named executive officers.

auto_awesomeAnalysis

Stockholders approved the Sixth Amendment and Restatement of the 2020 Stock Incentive Plan. This approval authorizes the company to issue an additional 740,000 shares (post-reverse split) for equity compensation. If all these shares were issued, it would result in a potential dilution of approximately 10.78% for existing shareholders. This is a significant amount for a company that recently reported substantial doubt about its ability to continue as a going concern, as noted in its March 12, 2026 10-K filing. While common for employee incentives, the magnitude of potential dilution is notable given the company's financial context.